6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 14, 2016, Pages 1438-1446

  Hong, Sung Jin ^a,b   Shin, Dong Ho ^b   Kim, Jung Sun ^b   Kim, Byeong Keuk ^b   Ko, Young Guk ^b   Choi, Donghoon ^b   Her, Ae Young ^c   Kim, Yong Hoon ^c   Jang, Yangsoo ^b,d   Hong, Myeong Ki ^b,d  

^a Inje University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

coronary artery disease; drug eluting stent(s); dual antiplatelet therapy

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN I; TROPONIN T; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; EVEROLIMUS; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DUAL ANTIPLATELET THERAPY; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; THROMBOLYSIS IN MYOCARDIAL INFARCTION; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY THROMBOSIS; DEVICES; DRUG ADMINISTRATION; DRUG ELUTING STENT; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTOR; SOUTH KOREA; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ASPIRIN; CARDIOVASCULAR AGENTS; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; EVEROLIMUS; HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; REPUBLIC OF KOREA; RISK FACTORS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84971222740     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.04.036     Document Type: Article

References (30)

1. 1 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
2. 2 Schulz-Schupke, S., Byrne, R.A., Ten Berg, J.M., et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 36 (2015), 1252–1263.
3. 3 Gilard, M., Barragan, P., Noryani, A.A., et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 65 (2015), 777–786.
4. 4 Colombo, A., Chieffo, A., Frasheri, A., et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2097.
5. 5 Feres, F., Costa, R.A., Abizaid, A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
6. 6 Valgimigli, M., Campo, G., Monti, M., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
7. 7 Gwon, H.C., Hahn, J.Y., Park, K.W., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
8. 8 Kim, B.K., Hong, M.K., Shin, D.H., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
9. 9 Baber, U., Mehran, R., Sharma, S.K., et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 58 (2011), 1569–1577.
10. 10 Stefanini, G.G., Byrne, R.A., Serruys, P.W., et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 33 (2012), 1214–1222.
11. 11 Stefanini, G.G., Baber, U., Windecker, S., et al. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet 382 (2013), 1879–1888.
12. 12 Palmerini, T., Biondi-Zoccai, G., Della Riva, D., et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 379 (2012), 1393–1402.
13. 13 Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
14. 14 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
15. 15 Diletti, R., Serruys, P.W., Farooq, V., et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 164 (2012), 654–663.
16. 16 Smits, P.C., Hofma, S., Togni, M., et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 381 (2013), 651–660.
17. 17 Fokkema, M.L., James, S.K., Albertsson, P., et al. Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol 61 (2013), 1222–1230.
18. 18 Airoldi, F., Colombo, A., Morici, N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007), 745–754.
19. 19 Suh, J., Park, D.W., Lee, J.Y., et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. J Am Coll Cardiol Intv 3 (2010), 383–389.
20. 20 Naidu, S.S., Krucoff, M.W., Rutledge, D.R., et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. J Am Coll Cardiol Intv 5 (2012), 626–635.
21. 21 Kereiakes, D.J., Smits, P.C., Kedhi, E., et al. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II III, IV and COMPARE trials. Eurointervention 7 (2011), 74–83.
22. 22 Hong, S.J., Kim, B.K., Shin, D.H., et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JAMA 314 (2015), 2155–2163.
23. 23 Cutlip, D.E., Windecker, S., Mehran, R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
24. 24 Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. Circulation 126 (2012), 2020–2035.
25. 25 Moussa, I.D., Klein, L.W., Shah, B., et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol 62 (2013), 1563–1570.
26. 26 Serebruany, V.L., Atar, D., Assessment of bleeding events in clinical trials—proposal of a new classification. Am J Cardiol 99 (2007), 288–290.
27. 27 Dangas, G.D., Serruys, P.W., Kereiakes, D.J., et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). J Am Coll Cardiol Intv 6 (2013), 914–922.
28. 28 Kim, J.S., Kim, J.H., Shin, D.H., et al. Serial randomized comparison of strut coverage of everolimus- and first-generation sirolimus-eluting stents. Can J Cardiol 31 (2015), 723–730.
29. 29 Giustino, G., Baber, U., Sartori, S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 65 (2015), 1298–1310.
30. 30 Urban, P., Meredith, I.T., Abizaid, A., et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373 (2015), 2038–2047.